A Phase 2/3 interventional study of BR005-036C and BR005-036C in Migraine, With or Without Aura, sponsored by Brise Pharmaceuticals Co., Ltd.. Recruiting at 83 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-23.
Sponsored by Brise Pharmaceuticals Co., Ltd. · Phase 2/3, Interventional, and Treatment
Among 78 studies in Migraine Disorders with a site in China — 32 open to participants now, 39 under way, 10 of them phase 3. Migraine Disorders · China.
Among the 78 studies in Migraine Disorders with a site in China, this one is the 4th largest by planned enrollment of the 59 interventional ones, is one of 8 that started in 2026, is the only one in phase 2/3, reaches primary completion later than 31 of the 38 other live ones, and was the 75th registered.
1,657 studies on the registry are indexed under Migraine Disorders; 339 are open to participants now.
This study's planned enrollment of 2,079 is above the median of 80 across 1,269 interventional studies indexed under Migraine Disorders.
Browse Migraine Disorders studies →32 of the 78 studies in Migraine Disorders with a site in China are open now, in 12 countries. Each count lists the studies.
Of the 216 Migraine Disorders studies recruiting now, 65 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 36 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →78 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 8 started in 2026.
Median enrollment 260 across the 59 interventional studies, 330 across the 19 observational. Of the 28 that completed or were terminated, 10 (36%) have results posted.
22 of 78 have an industry lead sponsor. The 10 most frequent:
Brise Pharmaceuticals Co., Ltd. is the lead sponsor of 2 studies on the registry; 2 are open to participants now.
Brise Pharmaceuticals Co., Ltd. has 2 studies filed under Migraine Disorders — fewer than ten, so there is no comparison to draw.
9 of the studies in Migraine Disorders with a site in China that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06641466Phase 3PfizerA Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine | 2026-11-29 |
| NCT07347028Beijing Tiantan HospitalClinical Study of Myofascial Trigger Points(MTrPs) Injection in the Treatment of Knee Osteoarthritis(OA) | 2026-12-01 |
| NCT07347067Beijing Tiantan HospitalClinical Study of Myofascial Trigger Points(MTrPs) Injection in the Treatment of Chronic Migraine | 2026-12-01 |
| NCT06347276China National Center for Cardiovascular DiseasesCerebral Microembolization Associated With PFO Closure | 2026-12-31 |
| NCT06953622Peking University Third HospitalEstablishment of a Clinical and Prognostic Follow-up Cohort of Migraine Patients With Patent Foramen Ovale | 2026-12-31 |
Among the 78 studies in Migraine Disorders with a site in China, from their registry updates:
The purpose of this study is to compare the efficacy and safety of BR005-036C versus placebo in subjects with Acute Migraines
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: BR005-036C
Drug: BR005-036C
Drug: Placebo
Dose 1, Oral tablet
Dose 2, Oral tablet
Placebo tablet to match BR005-036C dose, Oral
Percentage of Participants with Freedom from Pain at 2 hours post-dose
Time frame: 2 hours post-dose
Percentage of Participants with Freedom from Most Bothersome Symptom (MBS) at 2 hours post-dose
Time frame: 2 hours post-dose
Percentage of Participants with Sustained Pain Freedom from 2 to 24 hours post-dose
Time frame: From 2 hours up to 24 hours post-dose
Percentage of Participants with Sustained Pain Freedom from 2 to 48 hours post-dose
Time frame: From 2 hours up to 48 hours post-dose
Percentage of Participants with Rescue Medication Use from 2 to 24 hours post-dose
Time frame: From 2 hours up to 24 hours post-dose
Percentage of Participants with Freedom from Functional Disability at 2 hours post-dose
Time frame: 2 hours post-dose
Percentage of Participants with Pain Relief at 2 hours post-dose
Time frame: 2 hours post-dose
Number of Participants With Adverse Events (AEs)
Time frame: On-treatment period was from the administration of study intervention and through the EOT visit, up to 9 days
Started Sep 2026 (actual). Primary completion is estimated for Jun 2028, 21 months after the start.
Of 12 phase 2/3 interventional studies under Migraine Disorders, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 23. This study's planned 21 months is above that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Brise Pharmaceuticals Co., Ltd.